Florida Senate
-
2025
CS for CS for SB 1356
By
the CommitteeCommittees on Fiscal Policy; and Education Postsecondary; and Senator Burton
and Senators Burton and Berman
589-02481-25594-03194-25 20251356c120251356c2
1 A bill to be entitled
3 párrafos sin cambios
2 An act relating to the Florida Institute for Pediatric
3 Rare Diseases; creating s. 1004.4211, F.S.;
4 establishing the Florida Institute for Pediatric Rare
5 Diseases within the Florida State University College
6 of Medicine; providing the goalspurpose of the institute;
7 providing the goals of the institute; requiring the
78 requiring the institute to establish and administer the Sunshine
89 the Sunshine Genetics Pilot Program for a specified period;
910 period; providing the purpose of the pilot program; providing
1011 providing institute responsibilities and duties relating to the
1112 relating to the pilot program; providing requirements for
1213 for participation in the pilot program and data collection
1314 collection and release in the pilot program; defining the term
1415 the term “health care practitioner”; providing reporting
1516 reporting requirements for the pilot program; establishing the
1617 establishing the Sunshine Genetics Consortium for specified purposes;
1718 specified purposes; requiring the consortium to be administered at the
1819 administered at the institute by an oversight board; providing for the
1920 providing for the membership and terms of the board; providing reporting
21 requirements for the consortium; specifying that
22 implementation of the act is subject to appropriation;
2023 providing meetingan andeffective reporting requirements for thedate.
21 consortium; providing appropriations; providing an
22 effective date.
2324
2425 Be It Enacted by the Legislature of the State of Florida:
2526
2627 Section 1. Section 1004.4211, Florida Statutes, is created
2728 to read:
2829
1004.4211
The Florida Institute for Pediatric Rare
29
30
Diseases; the Sunshine Genetics Pilot Program; the Sunshine
3031
Genetics Consortium.—
3132
(1)
The Florida Institute for Pediatric Rare Diseases is
3233
established within the Florida State University College of
3334
Medicine as a statewide resource for pediatric rare disease
3435
research and clinical care. The purpose of the institute is to
3536
improve the quality of life and health outcomes for children and
3637
families affected by rare diseases by advancing knowledge,
3738
diagnosis, and treatment of pediatric rare diseases through
3839
research, clinical care, education, and advocacy.
39
40
(2)
The goals of the institute are to:
4041
(a)
Conduct research to better understand the causes,
4142
mechanisms, and potential treatments for pediatric rare
4243
diseases, including leveraging emerging research methods.
4344
(b)
Develop advanced diagnostic and genetic screening tools
4445
and techniques to enable health care providers to identify rare
4546
diseases in newborns and children more rapidly, accurately, and
4647
economically.
4748
(c)
Provide comprehensive multidisciplinary clinical
4849
services and care for children with rare diseases. Such care may
49
50
include, but is not limited to, patient, family, and caregiver
5051
support and resources to help navigate the challenges associated
5152
with these conditions, support groups, and patient advocacy.
5253
(d)
Educate and train health care professionals, including,
5354
but not limited to, genetic counselors, pediatricians,
5455
scientists, and other specialists in the field of pediatric rare
5556
diseases.
5657
(e)
Establish collaborations with other research
5758
institutions, medical centers, patient and family advocacy
5859
organizations, and government agencies whenever deemed
59
60
appropriate by the institute director to share expertise, raise
6061
awareness, and promote a collective effort to tackle pediatric
6162
rare diseases.
6263
(3)(a)
The institute shall establish and administer the
6364
Sunshine Genetics Pilot Program to be administered for a period
6465
of 5 years. The pilot program shall provide newborn genetic
6566
screening, including, but not limited to, whole genome
6667
sequencing. Genetic screening shall be performed by the
6768
institute and institutional members of the oversight board upon
6869
approval of the oversight board.
69
70
(b)
The institute may establish partnerships with Florida
7071
universities and colleges and health care service providers to
7172
promote and assist in the implementation of the pilot program.
7273
(c)
The pilot program shall be an opt-in program and a
7374
parent of a newborn must provide consent to participate in the
7475
pilot program.
7576
(d)
The institute and institutional members of the
7677
oversight board shall release clinical findings of a newborn’s
7778
screening to the newborn’s health care practitioner and the
7879
newborn’s parent. As used in this paragraph, the term “health
79
80
care practitioner” means a physician or physician assistant
8081
licensed under chapter 458; an osteopathic physician or
8182
physician assistant licensed under chapter 459; an advanced
8283
practice registered nurse, registered nurse, or licensed
8384
practical nurse licensed under part I of chapter 464; a midwife
8485
licensed under chapter 467; a speech-language pathologist or
8586
audiologist licensed under part I of chapter 468; a dietitian or
8687
nutritionist licensed under part X of chapter 468; or a genetic
8788
counselor licensed under part III of chapter 483.
8889
(e)
The institute shall:
8990
1.
Maintain a secure database to collect and store all
9091
pilot program data, including, but not limited to, newborn
9192
genomics sequence data and deidentified newborn data.
9293
2.
Provide deidentified newborn data to members of the
9394
consortium pursuant to a data sharing agreement to support
9495
ongoing and future research.
9596
(f)
By December 1, 2030, the institute shall provide a
9697
report on the Sunshine Genetics Pilot Program to the Governor,
9798
the President of the Senate, and the Speaker of the House of
9899
Representatives. The report must include, at a minimum:
99
100
1.
Study population and enrollment metrics.
100101
2.
Whole genome sequencing metrics.
101102
3.
Clinical and public health impact.
102103
4.
Cost effectiveness and economic benefits.
103104
(4)(a)
The Sunshine Genetics Consortium is established to
104105
create a network of clinical and academic research
105106
professionals, geneticists, and physicians from state
106
universities and the state’s children’s hospitals to collaborate
107
with leaders in the genetic industry and build and support a
universities and this state’s children’s hospitals to
108
culture of collaborative research and the development of cutting
collaborate with leaders in the genetics industry and build and
109
edge genetic and precision medicine in the state. The consortium
support a culture of collaborative research and the development
110
shall:
of cutting-edge genetic and precision medicine in the state. The
111
consortium shall:
112
1.
Integrate state-of-the-art genomic sequencing
112113
technologies.
113114
2.
Advance research and the development of cutting edgecutting-edge
114115
genetic and precision medicine.
115116
3.
Leverage advancements in artificial intelligence
116117
utilization in genomics.
117118
4.
Develop educational opportunities for clinicians on
118119
genomic tools.
119
120
5.
Support the growth and education of geneticists to meet
120121
demand.
121122
6.
Solicit and leverage funds from nonprofits, private
122123
industry, and others for the purpose of expanding the Sunshine
123124
Genetics Pilot Program and to support genetic screenings by
124125
institutional members of the oversight board.
125126
7.
Promote patient care that supports families with
126127
children diagnosed with genetic disorders.
127128
8.
Report on the use of deidentified newborn data by
128129
members of the consortium.
129
130
(b)1.
The consortium shall be administered at the institute
130131
by an oversight board. The board shall convene at least once
131132
every 6 months.
132133
2.
The oversight board for the consortium shall consist of
133
the director of the institute who shall serve as chair and the
134
followingthe votingdirector membersof the institute, who shall serve 2-yearas terms:chair, and the
135
following voting members, who shall serve 2-year terms:
136
a.
One member nominated by the dean of the University of
136137
Florida’s College of Medicine and approved by the university’s
137138
president.
138139
b.
One member nominated by the dean of the University of
139
140
South Florida’s College of Medicine and approved by the
140141
university’s president.
141142
c.
One member nominated by the dean of the University of
142143
Miami’s School of Medicine and approved by the university’s
143144
president.
144145
d.
One member nominated by the dean of Florida
146
International University’s School of Medicine and approved by
147
the university’s president.
148
e.
One member nominated by Nicklaus Children’s Hospital and
149
approved by the hospital’s president and chief executive
150
officer.
151
f.
One member appointed by the Governor.
145152
eg.
One member appointed by the President of the Senate.
146
153
fh.
One member appointed by the Speaker of the House of
147154
Representatives.
148
155
3.
The board shall be responsible for the promotion and
149
156
oversight of the consortium, including, but not limited to, the
150157
nomination and appointment of members of the consortium.
151158
(c)
Beginning October 15, 2026, and annually thereafter,
152159
the consortium shall provide a report to the Governor, the
153
160
President of the Senate, and the Speaker of the House of
154
161
Representatives on research projects, research findings,
155
162
community outreach initiatives, and future plans for the
156163
consortium.
157 Section 2.
For the 2025-2026 fiscal year, the sum of $5
158
million in recurring funds is appropriated from the General
159
Revenue Fund to the Florida Institute for Pediatric Rare
160
Diseases.
161 Section 3.
For the 2025-2026 fiscal year, the sum of $20
162
million in nonrecurring funds is appropriated from the General
163
Revenue Fund to the Florida Institute for Pediatric Rare
164
Diseases for the implementation of the Sunshine Genetics Pilot
(5)
The provisions of this section shall be implemented to
165
Program established in s. 1004.4211, Florida Statutes.
the extent of available appropriations contained in the annual
166
General Appropriations Act for such purpose.
166167 Section 42. This act shall take effect July 1, 2025.